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Abstract
BACKGROUND & AIMS—Drug-induced liver injury (DILI) has features similar to those of 
other liver diseases including autoimmune hepatitis (AIH). We aimed to characterize the clinical 
and autoimmune features of liver injury caused by nitrofurantoin, minocycline, methyldopa, or 
hydralazine.
METHODS—We analyzed data from 88 cases of DILI attributed to nitrofurantoin, minocycline, 
methyldopa, or hydralazine included in the Drug-Induced Liver Injury Network prospective study 
from 2004 through 2014. Sera were collected from patients at baseline and follow-up examination 
and tested for levels of immunoglobulin G (IgG), antibodies to nuclear antigen (ANA), smooth 
muscle (SMA), and soluble liver antigen (SLA). An autoimmune score was derived on the basis of 
increases in levels of IgG, ANA, SMA, and SLA (assigned values of 0, 1+, or 2+). AIH-associated 
HLA DRB1*03:01 and DRB1*04:01 allele frequencies were compared with those of the general 
population (controls).
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RESULTS—Of the 88 cases, 80 were women (91%), 74% had hepatocellular injury, and 25% had 
severe injury. At the onset of DILI, 39% of cases had increased levels of IgG, 72% had increased 
levels of ANA, 60% had increased levels of SMA, and none had increases in SLA. A phenotype of 
autoimmunity (autoimmune score ≥2) was observed in 82% of cases attributed to nitrofurantoin 
and 73% of cases attributed to minocycline (73%) but only 55% of cases attributed to methyldopa 
and 43% of cases attributed to hydralazine (P = .16 for nitrofurantoin and minocycline vs 
methyldopa and hydralazine). We observed a decrease in numbers of serum samples positive for 
ANA (P = .01) or SMA (P < .001) and in autoimmune scores (P < .001) between DILI onset and 
follow-up. Similar percentages of patients with DILI had HLA-DRB1*03:01 (15%) and HLA-
DRB1*04:01 (9%) as controls (12% and 9%, respectively).
CONCLUSIONS—In analysis of data from the DILIN, we found that most cases of DILI 
attributed to nitrofurantoin or minocycline and about half of cases that were due to methyldopa 
and hydralazine have a phenotype of autoimmunity similar to AIH. These features decrease with 
recovery of the injury and are not associated with the typical HLA alleles found in patients with 
idiopathic AIH.
Keywords
Database Analysis; Toxicity; Hepatotoxicity; Immune Response; Immunoglobulin
Idiosyncratic drug-induced liver injury (DILI) affects an estimated 19 per 100,000 persons 
yearly and is a major cause of acute liver failure.1–3 Liver injury may occur as a result of 
direct toxicity but is more often idiosyncratic because of either metabolic or immunologic 
factors. Alternatively, liver cell damage may trigger a sensitization response to nuclear and 
actin autoantigens, resulting in B-cell mediated autoantibody production and cytotoxic T-cell 
responses that resemble what occurs in spontaneous, idiopathic autoimmune hepatitis (AIH). 
The presence of autoimmune features such as antinuclear antibodies (ANAs), smooth 
muscle antibodies (SMAs), and elevated immunoglobulin G (IgG) levels is not uncommon 
in DILI and may cause diagnostic confusion.4,5 Even liver histologic features of AIH such as 
presence of plasma cells, eosinophils, and hepatocyte rosettes may occur with drug-induced 
injury.6,7 For these reasons, differentiating DILI with concomitant autoimmune features 
from preexisting or new-onset AIH can be diagnostically challenging.8–10
Drugs best known to cause liver injury with autoimmune features include nitrofurantoin, 
minocycline, hydralazine, and methyldopa.7,11,12 Patients with these forms of DILI may 
have a rapid, beneficial response to corticosteroid therapy, but most can ultimately be 
withdrawn from treatment without relapse,12 whereas those with idiopathic AIH require 
long-term if not lifelong therapy.13 Although idiopathic AIH has been associated with 
genetic susceptibility loci, both inside and outside the major histocompatibility complex 
region,14–17 it has not been well-defined for drug-induced AIH. In this study we have 
analyzed the prevalence and the clinical relevance of the autoimmune phenotype in a cohort 
of patients with nitrofurantoin-, minocycline-, hydralazine-, and methyldopa-induced liver 
injury and have assessed the association of liver injury with or without autoimmune features 
with typical autoimmune HLA alleles.
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Methods
Patients
The subjects in this study were participants in the Drug-Induced Liver Injury Network 
(DILIN) prospective study, the details of which have been described.18–21 Briefly, all 
patients with suspected DILI presenting at participating clinical centers (Supplementary 
Table 1) were asked to enroll in a prospective study. Eligibility requirements included age 
older than 2 years, enrollment within 6 months of onset, and predetermined degrees of 
serum alanine (ALT) or aspartate (AST) aminotransferase or alkaline phosphatase (Alk P) 
levels or a total bilirubin of 2.5 mg/dL or above or an international normalized ratio above 
1.5. All cases were reviewed by the DILIN Causality Committee and assigned a causality 
score ranging from 1 to 5 in which 1 = definite (>95% likelihood), 2 = highly likely (75%–
95%), 3 = probable (50%–74%), 4 = possible (25%–49%), and 5 = unlikely (<25%).19,21 
Patients with known or suspected acetaminophen hepatotoxicity or a previous known history 
of AIH, primary sclerosing cholangitis, or bone marrow or liver transplant were excluded. A 
detailed medical and medication history was obtained at enrollment, and additional 
laboratory and radiologic testing was performed to exclude competing etiologies. All 
patients were asked to return 6 months after enrollment, and those with persistent 
abnormalities were asked to return at 12 and 24 months.
All patients were categorized for the pattern of liver injury by using the R ratio ([ALT/upper 
limit of the normal range (ULN)] ÷ [Alk P/ULN]): >5 = hepatocellular, <2 = cholestatic, and 
2–5 = mixed hepatic injury.20 The severity of the DILI episode was categorized as mild (1), 
moderate (2), moderate-hospitalized (3), severe (4), or fatal (5; death or liver transplantation 
within 6 months of onset).20 For the current analysis, all patients in whom nitrofurantoin, 
minocycline, methyldopa, or hydralazine was considered as the definite, highly likely, or 
probable cause were included. The protocol for this observational study was approved by the 
Institutional Review Boards at each clinical site and the data coordinating center. All 
enrolled subjects provided written informed consent.
Histopathology
Liver biopsy was not a required part of the DILIN prospective study, but if a biopsy was 
done as part of clinical care, requests were made for unstained slides from the biopsy to be 
sent to a central repository where stains were made and biopsies read by a hepatopathologist 
(D.E.K.) who was not given any clinical information. Biopsies were read in a formulaic 
manner for individual features and overall pattern of injury as previously described.22
Autoantibodies and Immunoglobulin Levels
To standardize for differences in autoantibody and IgG tests between different clinical 
centers, stored serum samples drawn within 6 months of onset of DILI were used to 
determine baseline autoantibody and IgG status. If available, samples from 6-, 12-, and 24-
month follow-up visits were also tested. The presence of ANA, SMA, and anti–soluble liver 
antigen (SLA) was tested by enzyme-linked immunosorbent assay (ELISA) (Quanta Lite; 
Inova Diagnostics, San Diego, CA), and results were categorized as negative (0), low-
positive (+1), or high-positive (+2), according to the manufacturer’s instructions. Serum IgG 
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levels were measured by using a standard immunoturbidimetric assay (Roche/Hitachi Cobas 
C system; Roche Diagnostics USA, Indianapolis, IN) and scored as 0 (≤1600 mg/dL: 
<ULN), +1 (1600–1760 mg/dL: 1.0–1.1 times ULN), or +2 (greater than 1760 mg/dL: >1.1 
times ULN). A total autoimmune score was the sum of the ANA, SMA, SLA, and IgG 
scores (range, 0–8). Patients were considered to have an autoimmune phenotype if the total 
score was 2 or above. The auto-antibody and IgG results were compared with a reference 
group of patients with other common causes of DILI: amoxicillin-clavulanate, isoniazid, and 
diclofenac (Supplementary Table 2). The presence of rash (+1), fever (+1), facial edema 
(+1), lymphadenopathy (+1), and eosinophilia >500/μL (+1) was recorded at baseline in all 
patients. Patients with a score of 2 or greater were considered to have an immunoallergic 
phenotype.
HLA Testing
Genetic testing for major histocompatibility complex alleles HLA-DRB1*03:01 and HLA-
DRB1*04:01 was performed by imputation from genotype data obtained by using the 
Illumina Human Exome BeadChip with HIBAG software (Illumina, San Diego, CA) for 
patients with available DNA samples at the Duke Center for Human Genome Variation.23 
Frequencies were compared with allele frequencies from 1,242,890 European whites 
included in the National Marrow Donor Program, previously described by Gregart et al24 
and publicly available at http://allelefrequencies.net.25
Results
Between September 2004 and February 2014, 1322 patients with suspected DILI were 
enrolled into the DILIN prospective study. Of the total, 94 (8%) were adjudicated as 
definitely, highly likely, or probably due to nitrofurantoin, minocycline, methyldopa, or 
hydralazine. Six of the cases were excluded because other drugs were judged to be possibly 
implicated (n = 5) or because of preexisting liver disease (n = 1, hepatitis C). Thus, the 
cohort for analysis included 88 cases, 42 due to nitrofurantoin, 28 minocycline, 11 
methyldopa, and 7 hydralazine.
Clinical Features at Onset
The demographic, clinical, and biochemical features of the 88 cases are shown by drug in 
Table 1. Patients with nitrofurantoin and hydralazine injury were typically elderly (median 
ages, 65 and 60 years, respectively,) whereas those with minocycline and methyldopa injury 
were younger (median ages, 19 and 29 years, respectively), reflecting the different 
conditions for which these agents are prescribed. All 4 agents were marked by a female 
preponderance. The racial distribution also varied by agent; the majority of cases of 
minocycline and nitrofurantoin occurred in non-Hispanic whites, but blacks accounted for a 
high proportion of methyldopa (55%) or hydralazine (43%) cases. Seven patients with 
methyldopa-induced liver injury were treated with this agent for hypertension during 
pregnancy. At the time of onset of liver injury, 3 patients (27%) were pregnant, and 4 (36%) 
had recently delivered but were continued on methyldopa.
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The latency to onset of injury varied widely from 4 days to more than 5 years. 
Nitrofurantoin and minocycline were marked by a majority of cases with latency above 6 
months (71% each) and many above a year (62% and 50%, respectively). In contrast, 
latencies beyond 6 months were uncommon with methyldopa (9%) and hydralazine (14%), 
and all were within 1 year. The pattern of liver injury was predominantly hepatocellular 
(74% overall; 65%–100%) and rarely cholestatic (9% overall; 0%–11%).
Course and Outcome
Severity scores were mild (absence of jaundice) in 33 (38%), moderate in 33 (38%), and 
severe in 22 (25%) (Table 1). The anicteric cases often had a long latency to onset. Sixteen 
of the 22 severe cases were due to nitrofurantoin, which accounted for 5 of the 6 fatal 
instances (3 liver transplants and 2 deaths). The fatality rate was 12% with nitrofurantoin 
injury, 14% with hydralazine, but 0% with methyldopa and minocycline. A total of 41 
patients (47%) received corticosteroid therapy for the liver injury, but the use of 
corticosteroids, initial dose, and subsequent dose modifications were at the discretion of the 
local treating physician.
The median follow-up after onset was 8 months (range, 0.1–35 months). Seventy-four 
patients survived the initial injury and were followed for at least 6 months. Fifteen patients 
(20%) still had liver test abnormalities at 6 months, and the chronicity rate was similar 
among the 4 drugs (17%–25%; Table 1). The residual liver injury at 6 months was generally 
mild; no patient had jaundice, and serum enzymes were only modestly or moderately 
elevated. The persistent abnormalities decreased over time and often resolved. At the time of 
the last visit (7 months–3 years after onset), 6 patients had abnormal liver test results; ALT 
values were raised in 3 (42, 58, and 610 U/L) and Alk P in 5 (126–222 U/L), but bilirubin 
values were normal in all (0.2–0.7 mg/dL). Four patients were suspected of having cirrhosis 
on the basis of imaging studies, and 3 were still on low doses of corticosteroids (n = 1) or 
azathioprine alone (n = 2). There were no late deaths from end-stage liver disease or liver 
cancer.
Autoimmune Features
Serum samples taken within 6 months of onset were available from 65 patients, 47 of which 
(72%) tested positive for ANA, 39 (60%) for SMA, but none for SLA. Serum IgG levels 
were elevated in 25 patients (39%) and were greater than 1.1 times ULN in 16 (25%). The 
autoimmune phenotype was present in 47 patients (72%) including 24 cases of 
nitrofurantoin (83%), 14 minocycline (74%), 6 methyldopa (60%), and 3 hydralazine (43%) 
injury (Table 1, Figure 1). In the control group of 67 selected subjects with liver injury 
attributed to amoxicillin/clavulanate (n = 33), isoniazid (n = 24), or diclofenac (n = 10), 15 
(22%) were positive for ANA and 9 (13%) for SMA, 6 (9%) had elevated IgG levels, and 11 
(16%) had an autoimmune phenotype (Supplementary Table 2, Figure 2). Autoimmune 
features were most common among the subjects with diclofenac injury; 50% had ANA, 30% 
had SMA, and 30% had elevated IgG levels, with 50% having the autoimmune phenotype.
Follow-up serum samples were available from 39 patients (61%), which showed a decline in 
autoantibody prevalence and both antibody and IgG levels (Figure 3). Eight of 27 patients 
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(30%) who were initially ANA positive were negative on follow-up, as were 8 of 23 (35%) 
who were initially SMA positive. Mean IgG levels fell during follow-up from 1536 mg/dL 
(range, 668–5105) to 1179 mg/dL (range, 718–2017) (P < .001). Neither the decrease in IgG 
levels nor the loss of autoimmune phenotype status was associated with corticosteroid 
treatment (P = .60) or the presence of abnormalities at 6 months (chronicity: P = .10) (data 
not shown).
Clinical Features Associated With the Autoimmune Phenotype
There were no significant differences in age, sex, race, body mass index, presence and types 
of clinical symptoms, pattern of enzyme elevations, bilirubin elevations, disease severity, 
chronic laboratory abnormalities, use of corticosteroids, and time to recovery between those 
with or without the autoimmune phenotype (Table 2). However, all 5 patients with available 
serum samples in the most severe group (5+) had autoimmune features, consisting of 3 
patients who underwent liver transplantation and 2 who died. Furthermore, the latency to 
onset was longer in patients with the autoimmune phenotype than in those without (median, 
277 days, range, 8–7032 vs 100 days, range, 13–1572, respectively; P = .03), particularly in 
nitrofurantoin and minocycline associated injury. The latency and pattern of serum enzyme 
elevations for each patient with depiction of whether there were autoimmune or 
immunoallergic features are shown in Figure 4.
Genetics
Fifty-one white patients with DILI that was due to nitrofurantoin (n = 30), minocycline (n = 
16), methyldopa (n = 2), or hydralazine (n = 3) had been genotyped by using Illumina 
Human Exome BeadChip.23 The allele frequencies of the idiopathic AIH risk alleles HLA-
DRB1*03:01 and DRB1*04:01 among patients were similar to those of population controls 
from the National Marrow Donor Program (DRB1*03:01: 15% vs 12%, respectively, P = .4; 
DRB1*04:01: 9% vs 9%, respectively, P = 1.0).24,25 Among the drug-induced cases, none 
were homozygotes or compound heterozygotes for these alleles. In addition, in those 
patients with available serum samples (n = 36), there was no association between the 
presence or absence of the autoimmune phenotype and either DRB1*03:01 (13% vs 17%, P 
= .7) or DRB1*04:01 (11% vs 11%, P = 1.0).
Histology
Baseline liver biopsies, performed within 28 days of DILI onset, were available in 21 
patients. Virtually all patients had interface and lobular hepatitis, which was usually marked 
or severe (Table 2). Thirteen of 18 patients (72%) with both an available biopsy and a serum 
sample had the autoimmune phenotype, and five (28%) did not. Plasma cells were increased 
in 9 cases (69%) with vs 3 cases (60%) without the autoimmune phenotype, whereas 
hepatocyte rosettes were seen in 10 cases (77%) with vs 4 cases (80%) without this 
phenotype (Table 2). In regard to overall histologic pattern, most cases (72%) were classified 
as having an acute hepatitic (n = 9) or combined hepatitic/cholestatic (n = 6) pattern. Two 
cases (1 nitrofurantoin and 1 minocycline) displayed a chronic hepatitic pattern, both of 
whom had mild liver injury with serum aminotransferase elevations but no jaundice and 
presented more than a year after starting the medication. The 2 fatal cases (1 nitrofurantoin 
and 1 hydralazine) with available liver histology displayed a pattern of massive necrosis. 
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One severe case due to hydralazine showed marked inflammation and bridging necrosis that 
were confluent in zone 3, and a more moderate case due to methyldopa showed a mixed or 
unclassifiable pattern. No patient had purely cholestatic hepatitis or bland cholestasis.
Discussion
Nitrofurantoin, minocycline, methyldopa, and hydralazine are well-known causes of DILI 
with autoimmune features.7,11,12 In this study, the proportion of cases of liver injury that 
were due to these drugs that displayed autoimmune features was found to be 70% for 
nitrofurantoin and minocycline compared with 40%–50% for hydralazine and methyldopa. 
Although autoimmune features were present in these cases, they were not overly prominent; 
IgG was only modestly elevated, and autoantibody reactivity was mild to moderate during 
the acute illness and improved with recovery. In addition, autoimmune markers were more 
frequent with severe hepatic injury and were most frequent in patients with a prolonged 
latency, especially with nitrofurantoin and minocycline. As noted in previous studies, these 4 
agents were infrequently associated with short latency liver injury (ie, <1 month) (n = 10, 
11%), but latencies of 1–6 months were not uncommon (n = 26, 30%), although they were 
somewhat less likely to be associated with autoimmune features.12,26–32
Although this study represents the largest cohort of investigated autoimmune-like DILI cases 
that were due to these 4 drugs, no statistically significant associations were found between 
the autoimmune phenotype and demographic or clinical features or with outcome and 
prognosis. However, the follow-up in this study was only 2 years and was incomplete in a 
proportion of cases, which makes it impossible to provide a complete overview and 
assessment of the long-term prognosis of patients with the autoimmune phenotype of DILI. 
However, the clinical and histologic similarity of cases with and without autoimmune 
features suggests that the presence of autoantibodies merely reflects the variability in clinical 
and biochemical expression of the injury, and perhaps all cases are immunologically 
mediated.
The strengths of this study included the large number of patients, the use of standardized 
assays for autoantibodies, and the ability to compare cases of AIH-like injury that were due 
to several drugs (and control agents). The weaknesses of the study were that the cases were 
managed by many different physicians and were not evaluated and treated in a standardized 
manner. For instance, decisions regarding liver biopsy and use of corticosteroids were at the 
discretion of the local physician and were not a part of the prospective DILIN protocol. 
Furthermore, the standardized ELISAs used have not been as well-characterized for 
sensitivity and specificity as conventional immunofluorescence tests.33 Nevertheless, these 
assays allowed for uniform testing of all specimens and did show differences between cases 
and controls as well as before and after recovery. The sensitivity and specificity of the ANA 
and SMA assays have been reported in the literature.33,34
In general, nitrofurantoin-associated liver injury tended to be more severe and more likely to 
persist than that associated with the other 3 agents. Indeed, all except 1 of the fatalities was 
attributed to nitrofurantoin. Thus, nitrofurantoin fell into the conundrum described by 
Professor Hyman Zimmerman: drugs that cause hepatocellular injury with jaundice 
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generally have a high fatality rate, in excess of 10% (referred to colloquially as “Hy’s 
Law”).35 Of interest, despite causing acute icteric hepatocellular injury, neither minocycline 
nor methyldopa had any associated mortality and rarely caused persistent and long-lasting 
chronic injury. In support of these findings in regard to minocycline, large case series of fatal 
DILI invariably list nitrofurantoin and often include hydralazine and methyldopa as causes 
but do not mention minocycline.1,3,18
This study also sought to assess the role of the idiopathic AIH risk alleles HLA-
DRB1*03:01 and -DRB1*04:01 in drug-induced AIH-like injury by using a candidate gene 
approach.14 The analysis and the absence of homozygotes and compound heterozygotes 
showed that neither alleles were overrepresented in this cohort when compared with 
population controls. These findings suggest that HLA-DRB1*03:01 and -DRB1*04:01 
alleles do not represent risk factors for nitrofurantoin-, minocycline-, methyldopa-, and 
hydralazine-induced liver injury and the associated autoimmune phenotype. It should be 
noted that although this is the largest series of its kind, this study had a low power to detect 
associations and that analyses were restricted to white cases and controls because the 
original association in sporadic AIH was identified in whites.
Conclusions
An autoimmune-like hepatitis occurs in most but not all patients with nitrofurantoin- and 
minocycline-induced liver injury and in at least half of those with methyldopa and 
hydralazine injury. The autoimmune phenotype is not associated with clinical outcome and 
may slowly resolve with discontinuation of the drug and recovery from the acute 
hepatocellular liver injury. Furthermore, the presence of autoimmune features is not 
associated with the typical HLA alleles found in idiopathic AIH, indicating that it does not 
represent drug-induced injury occurring in patients with a predisposition to AIH.
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Abbreviations used in this paper
AIH autoimmune hepatitis
Alk P alkaline phosphatase
ALT alanine aminotransferase
ANA antinuclear antibody
AST aspartate aminotransferase
DILI drug-induced liver injury
DILIN Drug-Induced Liver Injury Network
ELISA enzyme-linked immunosorbent assay
IgG immunoglobulin G
SLA soluble liver antigen
SMA smooth muscle antibody
ULN upper limit of the normal range
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Figure 1. 
Frequencies of ANA, SMA, and IgG positivity and autoimmune phenotype at baseline. 
Frequencies of ANA, SMA positivity, IgG levels, and autoimmune (AI) score in 65 DILI 
cases due to nitrofurantoin- (n = 29), minocycline- (n = 19), methyldopa- (n = 10), and 
hydralazine- (n = 7) induced liver injury with available stored serum samples.
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Figure 2. 
Comparison of autoimmune features with reference cohort. Comparison of ANA, SMA 
positivity, IgG levels, and autoimmune (AI) score between 65 cases due to nitrofurantoin (n 
= 29), minocycline (n = 19), methyldopa (n = 10), and hydralazine (n = 7) (Mit/Myn/Met/
Hyd) and 67 reference cases due to amoxicillin/clavulanate (n = 33), isoniazid (n = 24), and 
diclofenac (n = 10) (Aug/INH/Dic).
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Figure 3. 
Comparison of autoimmune features at baseline and 6 months of follow-up. Frequencies of 
ANA, SMA positivity, IgG levels, and autoimmune (AI) score at baseline and 6 months of 
follow-up of 39 cases due to nitrofurantoin-, minocycline-, hydralazine-, and methyldopa-
induced with available samples.
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Figure 4. 
Latency and pattern of injury. Time of onset to DILI in days (capped at 12 months) in 
nitrofurantoin (A), minocycline (B), methyldopa (C), and hydralazine (D) cases with 
available serum samples, stratified according to drug, pattern of injury, and autoimmune 
and/or immunoallergic phenotype. C, cholestatic; HC, hepatocellular; M, mixed.
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Table 1
Baseline Characteristics and Outcome
Nitrofurantoin (n = 42) Minocycline (n = 28) Methyldopa (n = 11) Hydralazine (n = 7)
Feature
 Age (y)a 65 (36–84) 19 (16–61) 29 (18–43) 60 (42–76)
 Female sex 42 (100%) 22 (79%) 11 (100%) 5 (71%)
 Race
  White 38 (91%) 22 (79%) 4 (36%) 4 (57%)
  Black 3 (7%) 3 (11%) 6 (55%) 3 (43%)
  Other 1 (2%) 3 (11%) 1 (9%) 0
 BMI (kg/m2)a 27 (17–47) 22 (18–30) 36 (23–50) 27 (24–45)
 Latency (mo)
  <1 5 (12%) 1 (4%) 1 (9%) 3 (43%)
  1–6 7 (17%) 7 (25%) 9 (82%) 3 (43%)
  6–12 4 (9%) 6 (21%) 1 (9%) 1 (14%)
  >12 26 (62%) 14 (50%) 0 0
Initial results
 ALT (U/L)a 739 (106–1700) 938 (74–2942) 1414 (206–3319) 558 (132–2018)
 AST (U/L)a 643 (106–2221) 765 (80–2504) 1601 (282–2077) 1046 (184–1410)
 Alk P (U/L)a 190 (80–688) 153 (74–783) 125 (83–346) 260 (188–607)
 R ratioa,b 7.1 (1.0–56.9) 16.6 (0.4–50.7) 21.4 (11.0–59.2) 2.1 (1.1–28.9)
 Bilirubin (mg/dL) 4.7 (0.3–27.5) 3.4 (0.2–16.7) 7.3 (0.5–17.6) 2.1 (0.3–29.7)
 Pattern of injuryb
  Hepatocellular 28 (67%) 23 (82%) 11 (100%) 3 (43%)
  Mixed 11 (26%) 2 (7%) 0 2 (29%)
  Cholestatic 3 (7%) 3 (11%) 0 2 (29%)
Symptoms, signs
 Jaundice 26 (62%) 14 (50%) 9 (82%) 3 (43%)
 Itching 18 (43%) 14 (50%) 6 (55%) 3 (43%)
 Rash 10 (24%) 5 (18%) 3 (27%) 1 (14%)
 Fever 11 (26%) 7 (25%) 3 (27%) 1 (14%)
 Eosinophilia 1 (2%) 2 (7%) 0 1 (17%)
Phenotype
 Immunoallergic 8 (19%) 3 (11%) 3 (27%) 1 (14%)
 Autoimmune 24/29 (83%) 14/19 (74%) 6/10 (60%) 3/7 (43%)
Course and outcome
 Severity scorec
  Mild (1+) 17 (41%) 12 (43%) 2 (18%) 2 (29%)
  Moderate (2+, 3+) 9 (21%) 14 (50%) 7 (64%) 3 (43%)
  Severe (4+, 5+) 16 (38%) 2 (7%) 2 (18%) 2 (29%)
 Severity scorea 3 (1–5) 2 (1–4) 3 (1–4) 3 (1–5)
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Nitrofurantoin (n = 42) Minocycline (n = 28) Methyldopa (n = 11) Hydralazine (n = 7)
 Liver transplant 3 (8%) 0 0 1 (14%)
 Death 2 (5%) 0 0 0
 Corticosteroid therapy 20 (48%) 14 (50%) 3 (27%) 4 (57%)
Chronicity (6 mo)d 6/33 (18%) 6/24 (25%) 2/10 (20%) 1/7 (17%)
Chronicity (last value)d 3/33 (9%) 2/24 (8%) 0/10 (0%) 1/7 (17%)
BMI, body mass index.
a
Median (range).
b
Definitions: R ratio = (ALT/ULN) ÷ (Alk P/ULN). Hepatocellular, R ratio >5; Mixed, R ratio 2–5; Cholestatic, R ratio <2.
cSeverity scores: Mild, serum enzyme elevations without jaundice; Moderate, serum enzyme elevations and jaundice (bilirubin >2.5 mg/dL); 
Severe, evidence of hepatic failure, death, or liver transplantation within 6 months of onset.
dChronicity = abnormal ALT, Alk P, or bilirubin values at 6 months or thereafter.
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Table 2
Clinical Characteristics of Cases With and Without Autoimmune Features
Autoimmune (n = 47) Non-autoimmune (n = 18) P value
Features
 Age (y)a 53.1 (16–84) 43.3 (18–77) .4
 Female sex 43 (92%) 15 (83%) .4
 Race
  White 33 (70%) 13 (72%) .4
  Black 11 (23%) 4 (22%)
  Other 3 (6%) 1 (5%)
 BMI (kg/m2) 26.8 (18.2–49.9) 24.6 (17.7–49.5) .5
 Latency
  Latency (days)a 277 (8–7032) 100 (13–1572) .03
  <1 mo 4 (9%) 5 (28%)
  1–6 mo 16 (34%) 7 (39%) .1
  6–12 mo 5 (11%) 2 (11%)
  >12 mo 22 (47%) 4 (22%)
Initial results
 ALT (U/L)a 954 (74–3700) 1237 (108–3242) .5
 AST (U/L)a 867 (172–2504) 923 (97–2221) .9
 Alk P (U/L)a 176 (74–783) 188 (83–607) .9
 R ratioa,b 14.4 (0.4–82.4) 14.0 (1.1–59.2) .8
 Bilirubin (mg/dL)a 6.3 (0.3–27.5) 4.7 (0.3–29.7) .4
 Pattern of injuryb
  Hepatocellular 35 (74%) 14 (78%) .8
  Mixed 8 (17%) 2 (11%)
  Cholestatic 4 (9%) 2 (11%)
Symptoms, signs
 Jaundice 32 (68%) 10 (56%) .4
 Itching 25 (53%) 8 (44%) .6
 Rash 9 (19%) 4 (22%) .7
 Fever 15 (32%) 3 (17%) .4
 Eosinophilia 1 (2%) 3 (19%) .05
Phenotype
 Immunoallergic 9 (19%) 3 (17%) 1.0
 Autoimmune 47 (100%) 0 (0%)
Course and outcome
 Severity scorec
  Mild (1+) 15 (32%) 5 (28%) .4
  Moderate (2+, 3+) 18 (38%) 10 (56%)
  Severe (4+, 5+) 14 (30%) 3 (17%)
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Autoimmune (n = 47) Non-autoimmune (n = 18) P value
 Severity scored 2.6 (1–5) 2.6 (1–4) .8
 Liver transplant 3 (6%) 0 .6
 Death 2 (4%) 0 1.0
 Corticosteroid therapy 20 (43%) 11 (61%) .3
 Chronicity (6 mo)e 7/41 (17%) 3/14 (21%) .70
 Histologic features (n = 13) (n = 5)
  Interface hepatitis 13 (100%) 5 (100%)
  Plasma cells 9 (69%) 2 (40%)
  Hepatocyte rosettes 10 (77%) 4 (80%)
  Acute hepatitic pattern 7 (54%) 2 (40%)
  Chronic hepatitic pattern 0 1 (20%)
BMI, body mass index.
a
Median (range).
b
R ratio = (ALT/ULN) ÷ (Alk P/ULN). Hepatocellular, R ratio >5; Mixed, R ratio 2–5; Cholestatic, R ratio <2.
cSeverity score: Mild = serum enzyme elevations without jaundice; Moderate = serum enzyme elevations and jaundice (bilirubin >2.5 mg/dL); 
Severe = jaundice and evidence of hepatic failure, death, or liver transplantation within 6 months of onset.
dChronicity = abnormal ALT, Alk P, or bilirubin values at 6 months.
e
Mean (range).
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